Update and Critique of Natural Remedies as Antidepressant Treatments

Psychiatric Clinics of North America

Volumn 30, Issue 1, 2007, Pages 51-68

  Mischoulon, David ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; FISH OIL; HYPERICUM EXTRACT; ICOSAPENTAENOIC ACID; OLIVE OIL; OMEGA 3 FATTY ACID; PLACEBO; S ADENOSYLMETHIONINE;

BLEEDING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; FISHY AFTERTASTE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERICUM PERFORATUM; MEDICINAL PLANT; PHOTOTOXICITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TASTE AVERSION; XEROSTOMIA;

COMPLEMENTARY THERAPIES; DEPRESSIVE DISORDER; FATTY ACIDS, OMEGA-3; HUMANS; HYPERICUM; PHYTOTHERAPY;

EID: 33847692328     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2006.12.003     Document Type: Review

References (98)

1. Schulz V., Hansel R., and Tyler V.E. Rational phytotherapy: a physician's guide to herbal medicine. 4th edition (2001), Springer, Berlin p. 78-86
2. National Institutes of Health Office of Alternative Medicine 1997. Clinical practice guidelines in complementary and alternative medicine. An analysis of opportunities and obstacles. Practice and Policy Guidelines Panel. Arch Fam Med 6 (1997) 149-154
3. Eisenberg D.M., Kessler R.C., Foster C., et al. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 328 (1993) 246-252
4. Krippner S. A cross cultural comparison of four healing models. Alternative therapies. Health and Medicine 1 (1995) 21-29
5. Mischoulon D. Nutraceuticals in psychiatry, part 1: social, technical, economic, and political perspectives. Contemporary Psychiatry 2 11 (2004) 1-6
6. Mischoulon D. Nutraceuticals in psychiatry, part 2: review of six popular psychotropics. Contemporary Psychiatry 3 1 (2004) 1-8
7. National Institutes of Health Office of Alternative Medicine. Alternative medicine: expanding medical horizons (1992), National Institutes of Health Office of Alternative Medicine, Rockville (MD)
8. Muller-Kuhrt L., and Boesel R. Analysis of hypericins in hypericum extract. Nervenheilkunde 12 (1993) 359-361
9. Staffeldt B., Kerb R., Brockmoller J., et al. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the Hypericum perforatum extract LI 160 in healthy volunteers. Nervenheilkunde 12 (1993) 331-338
10. Wagner H., and Bladt S. Pharmaceutical quality of hypericum extracts. Nervenheilkunde 12 (1993) 362-366
11. Müller W., and Rossol R. Effects of hypericum extract on the expression of serotonin receptors. Nervenheilkunde 12 (1993) 357-358
12. Thiele B., Ploch M., and Brink I. Modulation of cytokine expression by hypericum extract. Nevenheilkunde 12 (1993) 353-356
13. Teufel-Mayer R., and Gleitz J. Effects of long-term administration of hypericum extracts on the affinity and density of the central serotonergic 5-HT1 A and 5-HT2 A receptors. Pharmacopsychiatry 30 Suppl 2 (1997) 113-116
14. Nierenberg A.A., Mischoulon D., and DeCecco L. St. John's Wort: a critique of antidepressant efficacy and possible mechanisms of action. In: Mischoulon D., and Rosenbaum J. (Eds). Natural medications for psychiatric disorders: considering the alternatives (2002), Lippincott Williams & Wilkins, Philadelphia 3-12
15. Laakmann G., Schule C., Baghai T., et al. St. John's Wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31 Suppl 1 (1998) 54-59
16. Orth H.C., Rentel C., and Schmidt P.C. Isolation, purity analysis and stability of hyperforin as a standard material from Hypericum perforatum L. J Pharm Pharmacol 51 2 (1999) 193-200
17. Bladt S., and Wagner H. MAO inhibition by fractions and constituents of hypericum extract. Nervenheilkunde 12 (1993) 349-352
18. Linde K., Mulrow C.D., Berner M., et al. St John's wort for depression. Cochrane Database Syst Rev 2 (2005) CD000448
19. Vorbach E.U., Hubner W.D., and Arnoldt K.H. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine. Randomized double blind study with 135 out-patients. Nevernheilkunde 12 (1993) 290-296 Also in J Geriatr Psychiatry Neurol 1994 Oct;7 Suppl 1:S19-23
20. Harrer G., Hubner W.D., and Podzuweit H. Effectiveness and tolerance of the hypericum preparation LI 160 compared to maprotiline. Multicentre double-blind study with 102 outpatients. Nervenheilkunde 12 (1993) 297-301
21. Martinez B., Kasper S., Ruhrmann B., et al. Hypericum in the treatment of seasonal affective disorders. Nervenheilkunde 12 (1993) 302-307
22. Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients-a controlled 6-week clinical trial. Pharmacopsychiatry 30 Suppl 2 (1997) 77-80
23. Nierenberg A.A. St. John's Wort: a putative over-the-counter herbal antidepressant. Journal of Depressive Disorders, Index & Reviews III (1998) 16-17
24. Linde K., Ramirez G., Mulrow C.D., et al. St. John's wort for depression-an overview and meta-analysis of randomized clinical trials. Br Med J 313 (1996) 253-258
25. Volz H.P. Controlled clinical trials of hypericum extracts in depressed patients-an overview. Pharmacopsychiatry 30 Suppl 2 (1997) 72-76
26. Lecrubier Y., Clerc G., Didi R., et al. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 159 8 (2002) 1361-1366
27. Shelton R.C., Keller M.B., Gelenberg A., et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 285 15 (2001) 1978-1986
28. Brenner R., Azbel V., Madhusoodanan S., et al. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther 22 4 (2000) 411-419
29. Gastpar M., Singer A., and Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 38 2 (2005) 78-86
30. van Gurp G., Meterissian G.B., Haiek L.N., et al. St John's wort or sertraline? Randomized controlled trial in primary care. Can Fam Physician 48 (2002) 905-912
31. Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 15 2 (2000) 61-68
32. Behnke K., Jensen G.S., Graubaum H.J., et al. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther 19 1 (2002) 43-52
33. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA 287 (2002) 1807-1814
34. Fava M., Alpert J., Nierenberg A.A., et al. A double-blind, randomized trial of St. John's Wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 25 5 (2005) 441-447
35. Moreno R.A., Teng C.T., Almeida K.M., et al. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. Rev Bras Psiquiatr 28 1 (2006) 29-32 [Epub 2006 Mar 24]
36. Baede-van Dijk P.A., van Galen E., and Lekkerkerker J.F. [Drug interactions of Hypericum perforatum (St. John's wort) are potentially hazardous]. Ned Tijdschr Geneeskd 144 17 (2000) 811-812 (Article in Dutch)
37. Miller L.G. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 158 (1998) 2200-2211
38. Moore L.B., Goodwin B., Jones S.A., et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 97 13 (2000) 7500-7502
39. Miller J.L. Interaction between indinavir and St. John's wort reported. Am J Health Syst Pharm 57 7 (2000) 625-626
40. Piscitelli S.C., Burstein A.H., Chaitt D., et al. Indinavir concentrations and St John's wort. Lancet 355 9203 (2000) 547-548
41. Hu Z., Yang X., Ho P.C., et al. Herb-drug interactions: a literature review. Drugs 65 9 (2005) 1239-1282
42. Schulz V. Safety of St. John's Wort extract compared to synthetic antidepressants. Phytomedicine 13 3 (2006) 199-204 [Epub 2005 Nov 2]
43. Woelk H., Burkhard G., and Grunwald J. Evaluation of the benefits and risks of the hypericum extract LI 160 based on a drug monitoring study with 3250 patients. Nervenheilkunde 12 (1993) 308-313
44. Beattie P.E., Dawe R.S., Traynor N.J., et al. Can St John's wort (hypericin) ingestion enhance the erythemal response during high-dose ultraviolet A1 therapy?. Br J Dermatol 153 6 (2005) 1187-1191
45. Brockmoller J., Reum T., Bauer S., et al. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 30 Suppl 2 (1997) 94-101
46. Siegers C.P., Biel S., and Wilhelm K.P. Phototoxicity caused by hypericum. Nervenheilkunde 12 (1993) 320-322
47. Stevinson C., and Ernst E. Can St. John's wort trigger psychoses?. Int J Clin Pharmacol Ther 42 9 (2004) 473-480
48. Spillmann M., and Fava M. S-adenosyl-methionine (ademethionine) in psychiatric disorders. CNS Drugs 6 (1996) 416-425
49. Alpert J.E., Mischoulon D., Nierenberg A.A., et al. Nutrition and depression: focus on folate. Nutrition 16 (2000) 544-546
50. Coppen A., and Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 60 (2000) 121-130
51. Alpert J.E., Mischoulon D., Rubenstein G.E.F., et al. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry 14 (2002) 33-38
52. Fava M., Borus J.S., Alpert J.E., et al. Folate, B12, and homocysteine in major depressive disorder. Am J Psychiatr 154 (1997) 426-428
53. Bottiglieri T., Godfrey P., Flynn T., et al. Cerebrospinal fluid s-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral s-adenosylmethionine. J Neurol Neurosurg Psychiatr 53 (1990) 1096-1098
54. Bell K.M., Potkin S.G., Carreon D., et al. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand Suppl 154 (1994) 15-18
55. Bottiglieri T., Chary T.K., Laundy M., et al. Transmethylation in depression. Ala J Med Sci 25 (1988) 296-301
56. Matthysse S., and Baldessarini R.J. S-adenosylmethionine and catechol-O-methyl-transferase in schizophrenia. Am J Psychiatry 128 (1972) 1310-1312
57. Tolbert L.C. MAT kinetics in affective disorders and schizophrenia. An account. Ala J Med Sci 25 (1988) 291-296
58. Bressa G.M. S-Adenosyl-l-Methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand 154 Suppl (1994) 7-14
59. Papakostas G.I., Alpert J.E., and Fava M. S-Adenosyl methionine in depression: a comprehensive review of the literature. Curr Psychiatry Rep 5 (2003) 460-466
60. Mischoulon D., and Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 76 5 Suppl (2002) 1158S-1161S
61. Fava M., Giannelli A., Rapisarda V., et al. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Psychiatry Res 56 (1995) 295-297
62. Alvarez E., Udina C., and Guillamat R. Shortening of latency period in depressed patients treated with SAMe and other antidepressant drugs. Cell Biol Rev S1 (1987) 103-110
63. Berlanga C., Ortega-Soto H.A., Ontiveros M., et al. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 44 (1992) 257-262
64. Alpert J.E., Papakostas G., Mischoulon D., et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol 24 6 (2004) 661-664
65. Carney M.W.P., Chary T.N.K., and Bottiglieri T. Switch mechanism in affective illness and oral S-adenosylmethionine (SAM). Br J Psychiatry 150 (1987) 724-725
66. Carney M.W., Martin R., Bottiglieri T., et al. Switch mechanism in affective illness and S-adenosylmethionine. Lancet 1 (1983) 820-821
67. Adams P.B., Lawson S., Sanigorski A., et al. Arachidonic acid to eicosapentaenoic acid ration in blood correlates positively with clinical symptoms of depression. Lipids 31 (1996) 157-161
68. Hibbeln J.R., and Salem Jr. N. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr 62 (1995) 1-9
69. Cross-National Collaborative Group. The changing rate of major depression: cross national comparisons. JAMA 268 (1992) 3098-3105
70. Hibbeln J.R. Fish consumption and major depression. [letter]. Lancet 351 (1998) 1213
71. Hibbeln J.R. Long-chain polyunsaturated fatty acids in depression and related conditions. In: Peet M., Glen I., and Horrobin D.F. (Eds). Phospholipid spectrum disorder in psychiatry (1999), Marius Press, Carnforth (UK) 195-210
72. Stoll A.L., and Locke C.A. Omega-3 fatty acids in mood disorders: a review of neurobiological and clinical actions. In: Mischoulon D., and Rosenbaum J. (Eds). Natural medications in psychiatric disorders (2002), Lippincott Williams & Wilkins, Philadelphia 13-34
73. Hamazaki K., Itomura M., Huan M., et al. Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial. Nutrition 21 6 (2005) 705-710
74. Murck H., Song C., Horrobin D.F., et al. Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression. Int J Neuropsychopharmacol 7 3 (2004) 341-349
75. Peet M., and Horrobin D.F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 59 10 (2002) 913-919
76. Su K.P., Huang S.Y., Chiu C.C., et al. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 13 4 (2003) 267-271
77. Nemets B., Stahl Z.M., and Belmaker R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 159 (2002) 477-479
78. Frangou S., Lewis M., and McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 188 (2006) 46-50
79. Silvers K.M., Woolley C.C., Hamilton F.C., et al. Randomized double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids 72 (2005) 211-218
80. Marangell L.B., Martinez J.M., Zboyan H.A., et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 160 5 (2003) 996-998
81. Freeman M.P., Hibbeln J.R., Wisner K.L., et al. Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand 113 1 (2006) 31-35
82. Marangell L.B., Martinez J.M., Zboyan H.A., et al. Omega-3 fatty acids for the prevention of postpartum depression: negative data from a preliminary, open-label pilot study. Depress Anxiety 19 1 (2004) 20-23
83. Stoll A.L., Severus E.W., Freeman M.P., et al. Omega3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 56 (1999) 407-412
84. Keck Jr. P.E., Mintz J., McElroy S.L., et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 60 (2006) 1020-1022
85. Parker G., Gibson N.A., Brotchie H., et al. Omega-3 fatty acids and mood disorders. Am J Psychiatry 163 6 (2006) 969-978
86. Osher Y., Bersudsky Y., and Belmaker R.H. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry 66 6 (2005) 726-729
87. Zanarini M.C., and Frankenburg F.R. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 160 (2003) 167-169
88. Mellor J.E., Laugharne J.D.E., and Peet M. Omega-3 fatty acid supplementation in schizophrenic patients. Hum Psychopharmacol 11 (1996) 39-46
89. Vaddadi K.S., Courtney T., Gilleard C.J., et al. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res 27 (1989) 313-323
90. Emsley R., Myburgh C., Oosthuizen P., et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 159 (2002) 1596-1588
91. Fenton W.S., Dickerson F., Boronow J., et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158 (2001) 2071-2074
92. Maidment I.D. Are fish oils an effective therapy in mental illness-an analysis of the data. Acta Psychiatr Scand 102 (2000) 3-11
93. Fux M., Benjamin J., and Nemets B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. J Psychiatr Res 38 3 (2004) 323-325
94. Peet M., Brind J., Ramchand C.N., et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 49 3 (2001) 243-251
95. Freeman M.P., Hibbeln J.R., Wisner K.L., et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatr 67 (2006) 1954-1967
96. Chiu C.-C., Huang S.-Y., Shen W.W., et al. Omega-3 fatty acids for depression in pregnancy. [letter]. Am J Psychiatry 160 (2003) 385
97. Eisenberg D.M. Advising patients who seek alternative medical therapies. Ann Intern Med 127 1 (1997) 61-69
98. Mischoulon D., and Rosenbaum J.F. The use of natural medications in psychiatry: a commentary. Harv Rev Psychiatry 6 (1999) 279-283